“when both beta-amyloid and tau are present in the brain, it can no longer be considered a risk factor, but rather a diagnosis,” said rik ossenkoppele, first author of the study and senior researcher at lund university and amsterdam university medical center. “a pathologist who examines samples from a brain like this, would immediately diagnose the patient with alzheimer’s.”
the study illustrates two schools of thought common among alzheimer’s researchers: those who believe the disease cannot be diagnosed until the emergence of cognitive impairment and those, like hansson and his team, who say diagnosis can and should be made purely based on biology and what they see happening in the brain.
“you can, for example, compare our results to
prostate cancer,” said rik ossenkoppele, an associate professor in translational neuroscience. “if you perform a biopsy and find cancer cells, the diagnosis will be cancer, even if the person in question has not yet developed symptoms.”
the team of researchers has watched with interest as positive results have emerged from clinical trials into lecanemab, a drug currently being administered to alzheimer’s patients.
“if we can diagnose the disease before cognitive challenges appear, we may eventually be able to use the drug to slow down the disease at a very early stage,” hansson said. “in combination with physical activity and good nutrition, one would then have a greater chance of preventing or slowing future cognitive impairment.